Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (480)	2/22/2001 2:10:23 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 1169

Hi tuck, You may want to listen to the CC. Link: vrtx.com The PR release: biz.yahoo.com VX-497 (merimempodib) -- Vertex has completed a preliminary analysis of a Phase II clinical trial of VX-497 in combination with interferon alpha. VX-497 is an IMPDH inhibitor in development by Vertex for the treatment of Hepatitis C. Following completion of the core study, patients have been rolled onto standard antiviral therapy consisting of ribavirin plus interferon alpha (Rebetron(TM)). The preliminary results of the core study indicate that further clinical development of VX-497 is warranted. The Company is continuing its analysis of the data with the goal of designing subsequent clinical trials in combination with the new long- lasting pegylated interferon products. Vertex retains worldwide commercial rights to VX-497. I do think there is a significant market in non-responders and non-tolerators to ribavirin and Intron A and that pegylation of the interferon alpha will not eliminate the martket opportunity, although it will reduce the market. ij